Voices
DESTINY-Breast06 Shows Clinical Benefit Across Patient Subgroups – Annals of Oncology
Annals of Oncology/sciencedirect.com

DESTINY-Breast06 Shows Clinical Benefit Across Patient Subgroups – Annals of Oncology

Annals of Oncology shared a post on X:

“An additional analysis of DESTINY-Breast06 shows that T-DXd provides consistent clinical benefit across patient subgroups, regardless of time to progression on 1L ET+CDK4/6i, type of endocrine resistance, or baseline burden of disease.”DESTINY-Breast06 Shows Clinical Benefit Across Patient Subgroups - Annals of Oncology

Title: Trastuzumab deruxtecan in hormone receptor–positive, HER2-low/-ultralow metastatic breast cancer (DESTINY-Breast06): outcome analyses by time to progression on prior first-line endocrine therapy with CDK4/6 inhibitor and baseline burden of disease

Authors: G. Curigliano, X. Hu, R. Dent, K. Yonemori, C.H. Barrios, J.-Y. Pierga, F. Puglisi, J.-M. Ferrero, K.H. Jung, N.A. Bagegni, J. Collignon, M. Gil-Gil, X. Wu, A. Andrzejuk-Ćwik, M. Schwaederle, S. Anand, A. Bardia

Read the Full Article.

 

DESTINY-Breast06 Shows Clinical Benefit Across Patient Subgroups - Annals of Oncology

Other articles about Annals of Oncology on OncoDaily.

A. Andrzejuk-Ćwik A. Bardia Annals of Oncology C. H. Barrios cancer DESTINY-Breast06 F. Puglisi G Curigliano J. Collignon J.-M. Ferrero J.-Y. Pierga K. Yonemori K.H. Jung M. Gil-Gil M. Schwaederle N.A. Bagegni OncoDaily Oncology R. Dent S. Anand X. Hu X. Wu